We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.
- Authors
De Pascale, Gennaro; Martucci, Gennaro; Montini, Luca; Panarello, Giovanna; Cutuli, Salvatore Lucio; Di Carlo, Daniele; Di Gravio, Valentina; Di Stefano, Roberta; Capitanio, Guido; Vallecoccia, Maria Sole; Polidori, Piera; Spanu, Teresa; Arcadipane, Antonio; Antonelli, Massimo
- Abstract
<bold>Background: </bold>Recent reports have suggested the efficacy of a double carbapenem (DC) combination, including ertapenem, for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-Kp) infections. We aimed to evaluate the clinical impact of such a regimen in critically ill patients.<bold>Methods: </bold>This case-control (1:2), observational, two-center study involved critically ill adults with a microbiologically documented CR-Kp invasive infection treated with the DC regimen matched with those receiving a standard treatment (ST) (i.e., colistin, tigecycline, or gentamicin).<bold>Results: </bold>The primary end point was 28-day mortality. Secondary outcomes were clinical cure, microbiological eradication, duration of mechanical ventilation and of vasopressors, and 90-day mortality. Forty-eight patients treated with DC were matched with 96 controls. Occurrence of septic shock at infection and high procalcitonin levels were significantly more frequent in patients receiving DC treatment (p < 0.01). The 28-day mortality was significantly higher in patients receiving ST compared with the DC group (47.9% vs 29.2%, p = 0.04). Similarly, clinical cure and microbiological eradication were significantly higher when DC was used in patients infected with CR-Kp strains resistant to colistin (13/20 (65%) vs 10/32 (31.3%), p = 0.03 and 11/19 (57.9%) vs 7/27 (25.9%), p = 0.04, respectively). In the logistic regression and multivariate Cox-regression models, the DC regimen was associated with a reduction in 28-day mortality (OR 0.33, 95% CI 0.13-0.87 and OR 0.43, 95% CI 0.23-0.79, respectively).<bold>Conclusions: </bold>Improved 28-day mortality was associated with the DC regimen compared with ST for severe CR-Kp infections. A randomized trial is needed to confirm these observational results.<bold>Trial Registration: </bold>ClinicalTrials.gov NCT03094494 . Registered 28 March 2017.
- Publication
Critical Care, 2017, Vol 21, p1
- ISSN
1364-8535
- Publication type
journal article
- DOI
10.1186/s13054-017-1769-z